Showing 1-1 of 1 grant
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Repurposing Colchicine for Reduction of Residual Inflammatory Risk in Type 1 Diabetes (REC1TE): A Randomized, Double-Blind, Placebo-Controlled, Investigator-Initiated Trial | Herlev Hospital | Asger Lund | Improving Lives | 01-December-2022 to 30-November-2027 | $1,288,599.00 |